R10040 |
IP-145; Duvelisib; INK1197 |
Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki
|
R10079 |
GSK2636771 |
GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitiv
|
R10107 |
NVPBKM120 |
BKM120 (NVP-BKM120, Buparlisib) is a selective PI3K inhibitor of p110α/β/δ/γ wit
|
R10168 |
YM201636 |
YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p11
|
R10210 |
BYL719 |
Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM i
|
R10243 |
GDC0941; Pictilisib |
Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell
|
R10373 |
GDC0941 |
Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell
|
R10607 |
CAL-101;GS-1101 |
CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM
|
R10622 |
Buparlisib Hydrochloride (BKM120 Hydrochloride) |
NVP-BKM120 Hydrochloride is a selective PI3K inhibitor of p110 with IC50 of 52 n
|
R10905 |
XL147; SAR245408 |
XL147 analogue is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/
|
R10907 |
AMG319 |
AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold
|
R10927 |
Pilaralisib;SAR245408;XL147 |
Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3
|
R10958 |
AS605240 |
AS-605240 selectively inhibits PI3Kγ with IC50 of 8 nM, over 30-fold and 7.5-fol
|
R10969 |
HS-173 |
HS-173 is a potent PI3Kα inhibitor with IC50 of 0.8 nM.
|
R10977 |
PIK-294 |
PIK-294 is a highly selective p110δ inhibitor with IC50 of 10 nM, 1000-, 49- and
|
R11896 |
deguelin |
Deguelin, a naturally occurring rotenoid, is a potent PI3K/AKT inhibit
|
R910225 |
gsk2292767 |
gsk2292767 is an effective selective PI3K δ inhibitor。
|